RJFSA
BDTX icon

Raymond James Financial Services Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$132K Buy
30,242
+13,000
+75% +$70.7K ﹤0.01% 3252
2024
Q2 		$80.3K Hold
17,242
– – ﹤0.01% 3264
2024
Q1 		$87.4K Buy
+17,242
New +$69.5K ﹤0.01% 3241

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Raymond James Financial Services Advisors's BDTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Black Diamond Therapeutics (BDTX) stake by 75% in Q3 2024, buying an estimated $70.7K and bringing the position to 30,242 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

Raymond James Financial Services Advisors first reported a position in BDTX in Q1 2024 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold BDTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 30,242 shares of Black Diamond Therapeutics worth $132K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 13,000 Black Diamond Therapeutics shares in Q3 2024, an estimated $70.7K.
  • Black Diamond Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3252 holding.
  • Raymond James Financial Services Advisors first reported a position in Black Diamond Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.